| Released | Contributor | Author | Title | Pages | Price |
| 8-Dec-2009 | New Constructs, LLC |
N/A
| LXRX: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 8-Dec-2009 | EconomicInvestor |
N/A
| "The Economy Matters" Report for LXRX: the economy's impact on LXRX's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
| 8-Dec-2009 | Pechala's Reports | Lubomir Pechala | LEXICON PHARMACEUTICALS INC (LXRX=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 7-Dec-2009 | Zacks Investment Research Inc. |
N/A
| LEXICON PHARMA (LXRX) Zacks Company Snapshot | 1 |
$10 |
| 7-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 7-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Consulting Industry Trends, Statistics & Analysis 2009 (Summary) | 29 |
$199 |
| 7-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 7-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Consulting Industry Market Research and Competitive Analysis 2009 | 408 |
$299 |
| 7-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for LXRX | 13 |
$25 |
| 5-Dec-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
1.10% Nasdaq 
Research Reports
